NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-AA-21-010 from the NIH Guide for Grants and Contracts. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) seeks applications to continue the previously funded Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD). Responsive applications are expected to address urgent and important unmet needs in the fetal alcohol spectrum disorders (FASD) field through an integrated and multidisciplinary research approach. These unmet needs include identifying FASD cases early and accurately, improving interventions to mitigate FASD outcomes; expanding basic and mechanistic understanding of alcohol teratogenesis aimed at accelerated translation, and reducing prenatal alcohol exposure and the incidence of FASD. Cooperative Agreement (U01) applications in response to this FOA should propose individual clinical or basic research projects.
Notice NOT-AR-22-003 from the NIH Guide for Grants and Contracts
Notice NOT-HD-21-039 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-21-035 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for Biomarker Characterization Centers (BCCs), one of the three scientific units of the Early Detection Research Network (EDRN). The EDRN is a national infrastructure to discover, develop, and validate biomarkers and imaging methods for early cancer detection and risk assessment. BCCs will (1) discover, develop, characterize and test new biomarkers or refine existing biomarkers, (2) develop, refine and/or standardize biomarker assays, (3) provide resources and support for the validation of biomarkers developed by the EDRN, and (4) participate in collaborative projects with other laboratories and centers. The other two scientific units of the continuing EDRN program are the Clinical Validation Centers (CVCs), which will conduct clinical research on the validation of biomarkers and will serve as resource centers for the Network by participating in collaborative biomarker validation studies with EDRN BCCs; and the Data Management and Coordinating Center (DMCC), which will support statistical and computational analyses, informatics infrastructure, study design, coordination and management of EDRN-sponsored biomarker validation studies, and the coordination of Network-wide meetings and workshops.
Funding Opportunity RFA-CA-21-034 from the NIH Guide for Grants and Contracts. The objectives of the Early Detection Research Network (EDRN; edrn.cancer.gov) are to discover, develop and validate biomarkers and imaging methods to detect early stage cancers and to translate these into clinical tests. The EDRN provides an infrastructure that is essential for this process and has successfully completed more than10 multicenter validation studies.
Funding Opportunity RFA-CA-21-033 from the NIH Guide for Grants and Contracts. The objectives of the Early Detection Research Network (EDRN; edrn.cancer.gov) are to discover, develop and validate biomarkers and imaging methods to detect early stage cancers and to translate these into clinical tests. The EDRN provides an infrastructure that is essential for this process and has successfully completed more than10 multicenter validation studies.
Notice NOT-OD-21-128 from the NIH Guide for Grants and Contracts
Notice NOT-GM-21-043 from the NIH Guide for Grants and Contracts
Notice NOT-GM-21-048 from the NIH Guide for Grants and Contracts
Notice NOT-GM-21-044 from the NIH Guide for Grants and Contracts
Notice NOT-GM-21-046 from the NIH Guide for Grants and Contracts
Notice NOT-GM-21-042 from the NIH Guide for Grants and Contracts
Notice NOT-GM-21-040 from the NIH Guide for Grants and Contracts
Notice NOT-GM-21-041 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-21-218 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to diversify the translational research workforce for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This initiative will emphasize the development of skills in data science and drug discovery and their application to various aspects of AD/ADRD research (from populations studies to research that can lead to new treatments and diagnostics, including all aspects of behavioral and social research). It will support research training of promising predoctoral candidates from diverse backgrounds to help them gain critical translational skills in data science and drug discovery. The long-term goal of this program is to develop a diverse translational workforce that can effectively participate in and/or lead a team-science, precision medicine approach to AD/ADRD treatment, prevention, early detection, and disease management and care.
Funding Opportunity PAR-21-217 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to diversify the translational research workforce for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This initiative will emphasize the development of skills in data science and drug discovery, and their application to various aspects of AD/ADRD research (from populations studies to research that can lead to new treatments and diagnostics, including all aspects of behavioral and social research). It will support research training of promising postdoctoral candidates from diverse backgrounds to help them gain critical translational skills in data science and drug discovery. The long-term goal of this program is to develop a diverse translational workforce that can effectively participate in and/or lead a team-science, precision medicine approach to AD/ADRD treatment, prevention, early detection, and disease management and care.
Funding Opportunity PAR-21-220 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to diversify the translational research workforce for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This initiative will emphasize the development of skills in data science and drug discovery, and their application to various aspects of AD/ADRD research (from populations studies to research that can lead to new treatments and diagnostics, including all aspects of behavioral and social research). This initiative will support early career, independent investigators from diverse backgrounds to gain critical translational skills in data science and drug discovery. The long-term goal of this program is to develop a diverse translational workforce that can effectively participate in and/or lead a team-science, precision medicine approach to AD/ADRD treatment, prevention, early detection, and disease management and care.
Notice NOT-MD-21-023 from the NIH Guide for Grants and Contracts
Notice NOT-OH-21-010 from the NIH Guide for Grants and Contracts
Notice NOT-GM-21-047 from the NIH Guide for Grants and Contracts